Journal
INNOVATION
Volume 1, Issue 2, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.xinn.2020.100041
Keywords
GASTROINTESTINAL CANCER; IMMUNE CHECKPOINT BLOCKADE; BIOMARKERS; PRECISION IMMUNOTHERAPY
Categories
Funding
- National Key Research and Development Program of China [2018YFC1313303]
Ask authors/readers for more resources
Gastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these patients remains poor. Recently, immunotherapy, involving programmed cell death-1 (PD-1) and its ligand (PD-L1), has shown promising efficacy in several solid cancers and seems to have become a potential treatment option for GI cancers This review focuses on data on the development of immunotherapy-based clinical trials in esophageal cancer, gastric cancer, and colorectal cancer. The predictive biomarkers and combination strategies in clinical trials and translational medicine are also discussed. Finally, prospects for immunotherapy in the treatment of GI cancers are described. Although only a small proportion of patients with GI cancers respond to PD-1/PD-L1 blockade, we strongly believe that precision immunotherapy might improve the overall survival of many more GI cancer patients in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available